InvestSMART

Starpharma Holdings Limited (ASX:SPL)

ALERT: Price-sensitive ASX Announcement for SPL
Current share price for SPL : $0.810 0.055 (7.28%)+
Announcement
Release
15 Jul 2026 9:15AM
Price at Release
$0.755
Full Release
download
Summary
Starpharma Holdings Limited is launching a fully underwritten approximately A$32 million pro-rata renounceable entitlement offer. The offer is a 1 for 7.5 entitlement offer at A$0.57 per new share, representing a 25% discount to the ASX traded closing price on 14 July 2026. The net proceeds from this offer will primarily fund clinical studies of DEP® HER2-Lu and the development of new targeted DEP® oncology assets. Post-offer, the estimated cash position is expected to be around $44.5 million, extending the cash runway into FY28. The company is focusing on strategic execution and revenue generation over the next 12-18 months, including the DEP® HER2-Lu program and other existing and new partner programs. Starpharma is a global leader in dendrimer technology with a clinically validated DEP® technology platform, novel radiopharmaceutical assets, and strong IP. The offer is fully underwritten by Canaccord Genuity (Australia) Limited.
Key Points
  • Fully underwritten A$32 million pro-rata renounceable entitlement offer.
  • Offer price set at A$0.57 per new share, a 25% discount to the last closing price.
  • Net proceeds to fund DEP® HER2-Lu clinical studies and new DEP® oncology assets.
  • Estimated post-offer cash position: $44.5 million.
  • Focus on strategic execution and revenue generation in the next 12-18 months.
  • Global leader in dendrimer technology with a clinically validated DEP® platform.
  • Offer underwritten by Canaccord Genuity (Australia) Limited.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.